These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. FDA's requirements for in-vitro performance data for prosthetic heart valves. Johnson DM; Chwirut DJ; Regnault WF J Heart Valve Dis; 1994 May; 3(3):228-34. PubMed ID: 8087255 [TBL] [Abstract][Full Text] [Related]
6. Comment on derivation of sample size requirements for evaluating heart valves with constant risk events. Korosteleva O; Lototsky S J Heart Valve Dis; 2003 Sep; 12(5):668-9; author reply 669. PubMed ID: 14565724 [No Abstract] [Full Text] [Related]
7. Does the Ross operation fulfil the objective performance criteria established for new prosthetic heart valves? Moidl R; Simon P; Aschauer C; Chevtchik O; Kupilik N; Rödler S; Wolner E; Laufer G J Heart Valve Dis; 2000 Mar; 9(2):190-4. PubMed ID: 10772035 [TBL] [Abstract][Full Text] [Related]
8. Clinical evaluation and analysis of heart valve substitutes. Grunkemeier GL; Anderson WN J Heart Valve Dis; 1998 Mar; 7(2):163-9. PubMed ID: 9587856 [TBL] [Abstract][Full Text] [Related]
9. The International Standard Cardiovascular implants--Cardiac Valve Prostheses (ISO 5840:1989) and the FDA Draft Replacement Heart Valve Guidance (Version 4.0). Nolan SP J Heart Valve Dis; 1994 Jul; 3(4):347-9. PubMed ID: 7952303 [No Abstract] [Full Text] [Related]
10. The new FDA guidelines. Bodnar E J Heart Valve Dis; 1994 May; 3(3):226-7. PubMed ID: 8087254 [No Abstract] [Full Text] [Related]
11. Bayesian stopping guidelines for heart valve premarket approval studies. Grunkemeier GL; Wu Y; Wang L; Hamilton C J Thorac Cardiovasc Surg; 2014 Dec; 148(6):2813-7.e1. PubMed ID: 25135236 [TBL] [Abstract][Full Text] [Related]
12. Experience with low-dose aspirin as thromboprophylaxis for the Tissuemed porcine aortic bioprosthesis: a survey of five years' experience. Goldsmith I; Lip GY; Mukundan S; Rosin MD J Heart Valve Dis; 1998 Sep; 7(5):574-9. PubMed ID: 9793859 [TBL] [Abstract][Full Text] [Related]
13. Risk-corrected impact of mechanical versus bioprosthetic valves on long-term mortality after aortic valve replacement. Lund O; Bland M J Thorac Cardiovasc Surg; 2006 Jul; 132(1):20-6. PubMed ID: 16798297 [TBL] [Abstract][Full Text] [Related]
14. Single-center outcome analysis of 1,161 patients with St. Jude medical and ATS open pivot mechanical heart valves. Bernet FH; Baykut D; Grize L; Zerkowski HR J Heart Valve Dis; 2007 Mar; 16(2):151-8. PubMed ID: 17484464 [TBL] [Abstract][Full Text] [Related]
15. Twenty-year comparison of tissue and mechanical valve replacement. Khan SS; Trento A; DeRobertis M; Kass RM; Sandhu M; Czer LS; Blanche C; Raissi S; Fontana GP; Cheng W; Chaux A; Matloff JM J Thorac Cardiovasc Surg; 2001 Aug; 122(2):257-69. PubMed ID: 11479498 [TBL] [Abstract][Full Text] [Related]
16. [The best of valvular heart disease in 2006]. de Gevigney G; Arch Mal Coeur Vaiss; 2007 Jan; 100 Spec No 1():19-28. PubMed ID: 17405561 [TBL] [Abstract][Full Text] [Related]